There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Background: T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematologic disease caused
by the transformation and uncontrolled proliferation of T-cell precursors. T-ALL is
generally thought to originate in the thymus since lymphoblasts express phenotypic
markers comparable to those described in thymocytes in distinct stages of development.
Although around 50% of T-ALL patients present a thymic mass, T-ALL is characterized
by peripheral blood and bone marrow involvement, and central nervous system (CNS)
infiltration is one of the most severe complications of the disease.
Summary: The CNS invasion is related to the expression of specific adhesion molecules and
receptors commonly expressed in developing T cells, such as L-selectin, CD44, integrins,
and chemokine receptors. Furthermore, T-ALL blasts also express neurotransmitters,
neuropeptides, and cognate receptors that are usually present in the CNS and can affect
both the brain and thymus, participating in the crosstalk between the organs.
Key Messages: This review discusses how the thymus-brain connections, mediated by innervation and
common molecules and receptors, can impact the development and migration of T-ALL
blasts, including CNS infiltration.
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.
The brain and the immune system are the two major adaptive systems of the body. During an immune response the brain and the immune system "talk to each other" and this process is essential for maintaining homeostasis. Two major pathway systems are involved in this cross-talk: the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). This overview focuses on the role of SNS in neuroimmune interactions, an area that has received much less attention than the role of HPA axis. Evidence accumulated over the last 20 years suggests that norepinephrine (NE) fulfills the criteria for neurotransmitter/neuromodulator in lymphoid organs. Thus, primary and secondary lymphoid organs receive extensive sympathetic/noradrenergic innervation. Under stimulation, NE is released from the sympathetic nerve terminals in these organs, and the target immune cells express adrenoreceptors. Through stimulation of these receptors, locally released NE, or circulating catecholamines such as epinephrine, affect lymphocyte traffic, circulation, and proliferation, and modulate cytokine production and the functional activity of different lymphoid cells. Although there exists substantial sympathetic innervation in the bone marrow, and particularly in the thymus and mucosal tissues, our knowledge about the effect of the sympathetic neural input on hematopoiesis, thymocyte development, and mucosal immunity is extremely modest. In addition, recent evidence is discussed that NE and epinephrine, through stimulation of the beta(2)-adrenoreceptor-cAMP-protein kinase A pathway, inhibit the production of type 1/proinflammatory cytokines, such as interleukin (IL-12), tumor necrosis factor-alpha, and interferon-gamma by antigen-presenting cells and T helper (Th) 1 cells, whereas they stimulate the production of type 2/anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta. Through this mechanism, systemically, endogenous catecholamines may cause a selective suppression of Th1 responses and cellular immunity, and a Th2 shift toward dominance of humoral immunity. On the other hand, in certain local responses, and under certain conditions, catecholamines may actually boost regional immune responses, through induction of IL-1, tumor necrosis factor-alpha, and primarily IL-8 production. Thus, the activation of SNS during an immune response might be aimed to localize the inflammatory response, through induction of neutrophil accumulation and stimulation of more specific humoral immune responses, although systemically it may suppress Th1 responses, and, thus protect the organism from the detrimental effects of proinflammatory cytokines and other products of activated macrophages. The above-mentioned immunomodulatory effects of catecholamines and the role of SNS are also discussed in the context of their clinical implication in certain infections, major injury and sepsis, autoimmunity, chronic pain and fatigue syndromes, and tumor growth. Finally, the pharmacological manipulation of the sympathetic-immune interface is reviewed with focus on new therapeutic strategies using selective alpha(2)- and beta(2)-adrenoreceptor agonists and antagonists and inhibitors of phosphodiesterase type IV in the treatment of experimental models of autoimmune diseases, fibromyalgia, and chronic fatigue syndrome.
Publication date Collection: January – December 2024 2024
Publication date
(Electronic):
16
February
2024
Volume: 31
Issue: 1
Pages: 51-61
Affiliations
[a
]Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio
de Janeiro, Brazil
[b
]Rio de Janeiro Research Network on Neuroinflammation, Oswaldo Cruz Institute, Oswaldo
Cruz Foundation, Rio de Janeiro, Brazil
[c
]National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM),
Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
[d
]INOVA-IOC Network on Neuroimmunomodulation, Oswaldo Cruz Foundation, Rio de Janeiro,
Brazil
[e
]Estácio de Sá University, Rio de Janeiro, Brazil
This work was supported by Fiocruz, Conselho Nacional de Desenvolvimento Científico
e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
– Rio de Janeiro, and the Mercosur Fund for Structural Convergence (FOCEM). It was
developed in the Brazilian National Institute of Science and Technology frameworks
on neuroimmunomodulation (CNPq) and the Rio de Janeiro Research Network on Neuroinflammation
(FAPERJ).
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.